Welcome to our dedicated page for Denali Capital Acquisition news (Ticker: DECA), a resource for investors and traders seeking the latest updates and insights on Denali Capital Acquisition stock.
Denali Capital Acquisition Corp. (DECA) is a special purpose acquisition company (SPAC) focused on identifying merger opportunities across diverse sectors. This news hub provides investors with essential updates on business combinations, regulatory filings, and corporate developments central to DECA's mission of creating public market opportunities for private enterprises.
Access real-time announcements covering proposed mergers, shareholder communications, and strategic partnership disclosures. Our curated collection includes SEC filings, investor presentations, and management commentary – all vital for understanding DECA's position in the evolving SPAC landscape.
Key updates include:
Business combination progress: Track merger target evaluations and transaction timelines
Regulatory milestones: Stay informed about SEC filings and compliance updates
Corporate governance: Monitor leadership changes and committee decisions
Market positioning: Analyze strategic moves within the competitive SPAC sector
Bookmark this page for streamlined access to DECA's latest developments. Investors can efficiently track this SPAC's journey from capital formation through potential merger completion, with all critical updates organized chronologically for quick reference.
Semnur Pharmaceuticals, a subsidiary of Scilex Holding Company (Nasdaq: SCLX), and Denali Capital Acquisition Corp. (Nasdaq: DECA) have signed a merger agreement for a proposed business combination. The deal values Semnur at $2.5 billion pre-transaction. The merger aims to create a publicly traded biopharma company focused on developing SP-102 (SEMDEXA™), a non-opioid treatment for sciatica with FDA Fast Track status. Projected annual sales for SEMDEXA™ are estimated at $1.5-$2.0 billion by the 5th year of launch. The transaction is expected to close by Q1 2025, with Scilex retaining majority ownership. The combined company will be renamed Semnur Pharmaceuticals, Inc., with its stock and warrants listed on Nasdaq under 'SMNR' and 'SMNRW'.
Denali Capital Acquisition Corp. (NASDAQ: DECA) has announced a one-month extension for completing its business combination, moving the deadline from August 11, 2024, to September 11, 2024. To fund this extension, the company deposited $15,063.74 into its trust account. The deposit was financed through a convertible promissory note issued to Scilex Holding Company (NASDAQ: SCLX) with a principal amount of up to $180,000. The note is interest-free and convertible into DECA's Class A ordinary shares at $10.00 per share upon closing a business combination. The remaining $164,963.26 of the note may be used for future extensions if needed.
Denali Capital Acquisition Corp. (NASDAQ: DECA) announced that shareholders have approved amendments to extend the deadline for completing a business combination from July 11, 2024, to April 11, 2025. The extension is set on a monthly basis, up to nine times, each by an additional month. The Company has deposited $15,063.74 into its trust account to fund the one-month extension to August 11, 2024, through a convertible promissory note with a principal amount up to $180,000 from the Sponsor. This note bears no interest and is repayable either upon a business combination's completion or the company's liquidation. Upon a successful business combination, the note can convert into Class A ordinary shares at $10.00 per share. Future drawdowns will likely fund subsequent one-month extensions. A detailed voting result will be filed with the SEC in a Current Report on Form 8-K.
Denali Capital Acquisition Corp. (NASDAQ: DECA) and Longevity Biomedical, Inc. have mutually decided to terminate their previously announced business combination agreement. This decision, announced on June 27, 2024, reflects a strategic shift for both parties. Denali, along with its sponsor, is now focusing on exploring alternative avenues to complete an initial business combination.
Denali Capital Acquisition Corp. (NASDAQ: DECA) announced the mutual termination of its business combination agreement with Longevity Biomedical, Inc. The decision was reached amicably by both parties. Moving forward, Denali, along with its sponsor, plans to explore other avenues for completing an initial business combination.
Denali Capital Acquisition Corp. (NASDAQ: DECA) announced on June 11, 2024, that it has deposited $50,000 into its trust account. This deposit extends the deadline for completing its business combination by one month, from June 11, 2024, to July 11, 2024. The extension aligns with the amended terms of the company's memorandum and articles of association.
Denali Capital Acquisition Corp. (DECA) has extended the deadline for completing its business combination by depositing $50,000 into its trust account, pushing the deadline to June 11, 2024. This move is in line with the amended terms of the Company's memorandum and articles of association.
FAQ
What is the current stock price of Denali Capital Acquisition (DECA)?
What is the market cap of Denali Capital Acquisition (DECA)?
